){kind=link}
Bioptik Technology 2025 Investor Presentation
NOVEMBER 27, 2025
Bioptik Technology Announces Key Highlights at 2025 Review & 2026 Outlook Meeting
Bioptik Technology 2025 Investor Presentation
Strengthening Global Strategy Across Multi-Function Monitoring, Diagnostics, and Healthcare Solutions
Bioptik Technology hosted its 2025 Review and 2026 Outlook Meeting on November 27, 2025, presenting a refined strategic roadmap centered on physiological monitoring, pathogen detection, and next-generation multi-parameter blood glucose systems designed for the rapidly expanding Southeast Asian and African markets. The briefing also highlighted new product opportunities, including advanced wound dressings and expanded home-use diagnostic solutions.
Enhanced R&D Capabilities to Accelerate Innovation
Bioptik currently operates three research and development centers in Taiwan, supported by a team of approximately 200 employees across biotechnology, medical diagnostics, immunology, engineering, and product design.
In 2025, the company established a new Biomedical Research & Development Division, which introduced a comprehensive functional verification platform to strengthen scientific validation for health supplements, skincare lines, wound-care materials, and medical diagnostic products. This initiative enhances Bioptik’s capability to deliver data-driven, efficacy-backed products aligned with global regulatory and clinical expectations.
In 2025, the company established a new Biomedical Research & Development Division, which introduced a comprehensive functional verification platform to strengthen scientific validation for health supplements, skincare lines, wound-care materials, and medical diagnostic products. This initiative enhances Bioptik’s capability to deliver data-driven, efficacy-backed products aligned with global regulatory and clinical expectations.
Global Presence and Product Portfolio Expansion
With more than 25 years of experience and market presence in over 70 countries, Bioptik has become a recognized innovator in:
˙Home-use medical monitoring systems (glucose, cholesterol, uric acid, hemoglobin, triglycerides)
˙Rapid test kits for human and veterinary applications
˙Health supplements and functional nutrition
˙Skincare and biomedical materials
Bioptik’s EU-certified devices and diversified product lines continue to drive its competitiveness in both consumer health and professional diagnostic markets.
˙Home-use medical monitoring systems (glucose, cholesterol, uric acid, hemoglobin, triglycerides)
˙Rapid test kits for human and veterinary applications
˙Health supplements and functional nutrition
˙Skincare and biomedical materials
Bioptik’s EU-certified devices and diversified product lines continue to drive its competitiveness in both consumer health and professional diagnostic markets.
2026 Outlook: New Products, New Regions, New Growth Momentum
In 2026, Bioptik will strengthen its presence in emerging markets—particularly Southeast Asia and Africa—leveraging its multi-parameter monitoring solutions and expanding product ecosystem. The company anticipates that new product pipelines, including advanced wound dressings and expanded biomarker detection technologies, will generate innovation-driven revenue growth and open new global partnerships.
Commitment to Sustainability and Corporate Responsibility
Bioptik actively advances ESG initiatives, focusing on:
˙Environmental stewardship through community coastal cleanups and sustainable manufacturing practices
˙Social impact programs supporting elderly health, community education, and preventive healthcare access
˙Governance excellence through transparent operations and international regulatory compliance
These initiatives demonstrate Bioptik’s long-term commitment to building a healthier and more sustainable future for communities in Taiwan and around the world.
˙Environmental stewardship through community coastal cleanups and sustainable manufacturing practices
˙Social impact programs supporting elderly health, community education, and preventive healthcare access
˙Governance excellence through transparent operations and international regulatory compliance
These initiatives demonstrate Bioptik’s long-term commitment to building a healthier and more sustainable future for communities in Taiwan and around the world.
communication after the meeting